Company info sheet for:

"Chemunex S.A. is a privately held French company incorporated in December 1984 and headquartered at 41, rue du 11 novembre 1918, 94700 Maisons-Alfort, near Pans, France. It also has a facility for manufacturing reagents at
Alfortville, near Paris, France and offices for sales and customer support in the United Kingdom, Germany, Italy and the United States."

"CHEMUNEX, a biotechnology company listed on EASDAQ end of March 1997, is a leader in the development and distribution of highly sensitive and rapid testing systems for the detection of microbial contamination in a variety of
industrial and consumers products , including pharmaceuticals, drinking water, cosmetics, foods and beverages. The innovative technology developed by the company over the last five years brings new standards of quality in the
industrial microbiology testing business. "


"Additionnally, the technology developed for highly sensitive microbial detection has potential applications for medical in vitro diagnostics in situations where the rapid detection of rare cells, such as tumour cells or
virus infected cells, can result in an early detection of a disease or a better monitoring of the therapy."

"PROSPECTS as at September 10th, 1997 - Sales for the the full year increased by over 85% to FF 18.0 million
(1996 : FF 9.7 million). In line with expectations, CHEMUNEX achieved placements of 15 ChemScan microbial analysers following its launch in the last quarter of 1996, predominantly to major multinational pharmaceutical companies. CHEMUNEX had a strong cash position of FF 103.9 million at June 30th, 1997. The Company believes it has enough cash for its foreseeable needs."


"Accelerated development efforts over the last year at Chemunex and under contract at The Technology Partnership (UK) have resulted in the launch ahead of schedule of the new model of ChemScan, which is going to be marketed under the ChemScan RDI trade name (Rapid Detection and Identification). Commercial shipments are expected to start in October 1997. Based on the company´s initial success, the Management is confident that placements of the ChemScan will now accelerate, both with new customers and through existing customers purchasing additional units for other plants or new applications. As a result of the ChemScan system progressively becoming part of routine microbial
testing, reagents sales are expected to increase steadily. "


"An attractive business opportunity for Chemunex is noticed in the North American market where the company´s cutting edge technology meets the needs of the industry for microbial testing. The US market is regarded as our number
one priority, and is being allocated human and financial resources accordingly. END. "